Abstract 2208P
Background
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung cancer which is frequently associated with EBV infection and displays high levels of immune cell infiltration. Immunotherapy, thus, is an attractive therapeutic strategy for the disease but the treatment response has been inconsistent, indicating a gap in our understanding of the tumor microenvironment (TME) of PLELC.
Methods
Imaging mass cytometry was used in this study to map the different cellular components and interactions in 33 PLELCs at different stages (19 early-stage, 6 medium-stage, and 8 advanced-stage).
Results
Component analysis showed differential B and Treg cell composition in the TME as cancer progresses. In spatial analyses, we discovered a convergent melting trend of immune cell distribution across different stages in the tumor and non-tumor regions (p<0.05). We also identified anti-tumor immunity markers assigned to specific cellular interactions (p<0.01). In the neighborhood analysis, we found that myeloid cells near the tumor may attenuate the ability of antigenic immune responses. Furthermore, we identified two spatial structures within the TME that could impact the infiltration of immune cells and the relapse of patients, and disease relapse in patients is associated with the level of immune cells inside the tumor region (p<0.01) and fibroblasts surrounding the tumor.
Conclusions
Our findings indicate that TME is heterogeneous and dynamic along the disease progression of PLELC such that cellular components, spatial interactions, and immune cell infiltration may play a significant role in disease recurrence. Moreover, profiling the TME may be helpful for understanding and selecting different immune treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2130P - ATTITUDE - ATTrition In longiTUDinal studiEs of cancer survivors (CS): Can we improve the experience of patients (pts)?
Presenter: Camila Chiodi
Session: Poster session 07
2131P - Real-life experiences from a late effects clinic: An investigation of health-related quality of life in Danish cancer survivors
Presenter: Lærke Tolstrup
Session: Poster session 07
2132P - Unmet needs, quality of life, and financial toxicity in survivors of lung cancer
Presenter: Josephine Feliciano
Session: Poster session 07
2133P - Sleep disorders: Evolution in time in early breast cancer (EBC)
Presenter: Blanca Cantos
Session: Poster session 07
2134P - Self-reported late effects, need for information and follow-up in long-term Hodgkin lymphoma survivors
Presenter: Lise Willumsen
Session: Poster session 07
2135P - Impact of geriatric assessment (GA) and geriatric 8(G8)-based targeted interventions on the quality of life (QoL) in older Asian adults with cancer
Presenter: Jia Li Low
Session: Poster session 07
2136P - Prostate cancer supportive care (PCSC) program for patients and partners: A model for meeting an unmet need for PC patients
Presenter: Celestia Higano
Session: Poster session 07
2137P - Impact of supportive care on the quality of life (QoL) of hospitalized cancer patients (pts)
Presenter: Judit Sanz Beltran
Session: Poster session 07
2138P - Time toxicity of palliative chemotherapy in a geriatric oncology population
Presenter: Christopher Cronin
Session: Poster session 07
2139P - Quality of life in adult cancer survivors (QLACS) in Spain: Study of its clinical characteristics and use of social media for oncological information
Presenter: Maria Cornide Santos
Session: Poster session 07